Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB/ SE0000872095 /
SOBI
|
31/05/2024 00:00:00
|
Chg.
+4.60
|
Volume |
Bid17:29:30 |
Demandez à17:29:30 |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
|
282.40SEK
|
+1.66%
|
706,896
Chiffrre d'affaires: 194.93 Mio. |
282.00Bid taille: - |
282.80Ask la taille: - |
100.28 Mrd.SEK |
- |
37.88 |
Description de l'entreprise
Swedish Orphan Biovitrum AB is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.
Conseil d'administration & Conseil de surveillance
| PDG |
| Guido Oelkers |
| Conseil d'administration |
| Henrik Stenqvist, Lydia Abad-Franch, Duane H. Barnes, Lena Bjurner, Sofiane Fahmy, Torbjörn Hallberg, Mahmood Ladha, Norbert Oppitz, Daniel Rankin, Armin Reininger, Christine Wesström |
| Conseil de surveillance |
| Annette Clancy, Christophe Bourdon, Helena Saxon, Staffan Schüberg, Katy Mazibuko, Mats Lek, Anders Ullman, Filippa Stenberg |
Données de l'entreprise
| Nom: |
Swedish Orphan Biovitrum AB |
| Adresse: |
Tomtebodavägen 23A,Solna 112 76 |
| Téléphone: |
+46-8-697-2000 |
| Fax: |
- |
| Courriel: |
-
|
| Internet: |
www.sobi.com |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
42.16% |
| IPO date: |
- |
Calendrier de l'entreprise
|
CW 29 | 16/07/2024
Interim Report 2nd Quarter/6 Months
|
|
CW 43 | 24/10/2024
Interim Report 3rd Quarter/9 Months
|
